Gaush Meditech's (HKG:2407) subsidiary Gaush Teleon obtained a class II medical device registration certificate for its self-developed intraocular lens implant system from the Guangdong Provincial Medical Products Administration, a Wednesday Hong Kong bourse filing said.
As of now, all cataract surgery therapies generally require intraocular lens implantation to treat problems like blindness due to cataracts, and high myopia, the filing said.
Gaush Teleon's intraocular lens implant system can be applied for cataract surgery and also in the implantation of phakic intraocular lenses for myopia treatment.
The ophthalmology medical business company's shares closed nearly 6% lower on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.